Management raised Q4 2025 revenue guidance to $21.4 million to $22.4 million and GAAP diluted EPS guidance to $0.43 to $0.47, with non-GAAP diluted EPS of $0.47 to $0.50. For full year 2025, guidance ...
Iradimed picked up an FDA nod for its MRI-compatible intravenous infusion pump system, which enables patients who can’t be disconnected from IV medication to undergo MRI scanning. The company will now ...
The global MRI-Compatible IV Infusion Pump Systems Market is estimated to be valued at USD 322.5 million in 2025 and is projected to reach USD 742.9 million by 2035, registering a compound annual ...
Roth MKM has resumed coverage of iRadimed (NASDAQ:IRMD) with a buy rating citing the company's position as the sole provider of MRI-compatible IV pumps. The firm has a $65 price target (~59% upside ...
Iradimed Corporation announced that it has received FDA 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System, making it the only supplier of non-magnetic MRI-compatible ...
Total Revenue-- $21.2 million for the third quarter of 2025, up 16%, driven by MRI compatible IV infusion pump and monitoring system growth. Gross Profit and Margin-- $16.4 million at 78% margin for ...
WINTER SPRINGS, Fla., May 11, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced the issuance by the U.S. Patent and Trademark Office of a patent that expands on previous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results